Leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia.
The adipocyte-derived hormone leptin is an important regulator of appetite and energy expenditure and is now appreciated for its ability to control innate and adaptive immune responses. We have reported previously that the leptin-deficient ob/ob mouse exhibited increased susceptibility to the Gram-negative bacterium Klebsiella pneumoniae. In this report we assessed the impact of chronic leptin deficiency, using ob/ob mice, on pneumococcal pneumonia and examined whether restoring circulating leptin to physiological levels in vivo could improve host defences against this pathogen. We observed that ob/ob mice, compared with wild-type (WT) animals, exhibited enhanced lethality and reduced pulmonary bacterial clearance following Streptococcus pneumoniae challenge. These impairments in host defence in ob/ob mice were associated with elevated levels of lung tumour necrosis factor (TNF)-alpha, macrophage inflammatory peptide (MIP)-2 [correction added after online publication 28 September 2007: definition of MIP corrected], prostaglandin E(2) (PGE(2)), lung neutrophil polymorphonuclear leukocyte (PMN) counts, defective alveolar macrophage (AM) phagocytosis and PMN killing of S. pneumoniae in vitro. Exogenous leptin administration to ob/ob mice in vivo improved survival and greatly improved pulmonary bacterial clearance, reduced bacteraemia, reconstituted AM phagocytosis and PMN H(2)O(2) production and killing of S. pneumoniae in vitro. Our results demonstrate, for the first time, that leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia. Further investigations are warranted to determine whether there is a potential therapeutic role for this adipokine in immunocompromised patients.
Hsu
A
A
Department of Environmental Health Sciences, Ann Arbor, MI, USA.
Aronoff
D M
DM
Phipps
J
J
Goel
D
D
Mancuso
P
P
D000818:Animals; D016470:Bacteremia / Q000188:drug therapy; D016207:Cytokines / Q000096:biosynthesis; D004198:Disease Susceptibility; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D006861:Hydrogen Peroxide / Q000378:metabolism; D020738:Leptin / Q000172:deficiency / Q000627:therapeutic use*; D007958:Leukocyte Count; D008168:Lung / Q000276:immunology / Q000382:microbiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D020556:Neutrophil Infiltration / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000302:isolation & purification / Q000472:pathogenicity*; D016019:Survival Analysis